Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?

Hoppenot C, Peters P, Cowan M, Moore ED, Hurteau J, Lee NK, Yamada SD.

Gynecol Oncol. 2019 Jul;154(1):177-182. doi: 10.1016/j.ygyno.2019.04.681. Epub 2019 May 2.

PMID:
31056111
2.

Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.

Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženović I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, Andrade J, Fiehn O, Moellering RE, Mann M, Lengyel E.

Nature. 2019 May;569(7758):723-728. doi: 10.1038/s41586-019-1173-8. Epub 2019 May 1.

PMID:
31043742
3.

Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.

Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K, Montag A, Yamada SD, López-Méndez B, Nilsson J, Mund A, Mann M, Curtis M.

Cell. 2018 Sep 20;175(1):159-170.e16. doi: 10.1016/j.cell.2018.08.065.

PMID:
30241606
4.

Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.

Curtis M, Kenny HA, Ashcroft B, Mukherjee A, Johnson A, Zhang Y, Helou Y, Batlle R, Liu X, Gutierrez N, Gao X, Yamada SD, Lastra R, Montag A, Ahsan N, Locasale JW, Salomon AR, Nebreda AR, Lengyel E.

Cell Metab. 2019 Jan 8;29(1):141-155.e9. doi: 10.1016/j.cmet.2018.08.007. Epub 2018 Aug 30.

PMID:
30174305
5.

Second primary rhabdomyosarcoma of the uterine cervix presenting with synchronous ovarian Sertoli-Leydig cell tumor: An illustrative case of DICER1 syndrome.

Cowan M, Suntum T, Olivas AD, Perpich M, Applebaum MA, Lastra RR, Yamada SD.

Gynecol Oncol Rep. 2018 Jun 15;25:94-97. doi: 10.1016/j.gore.2018.06.008. eCollection 2018 Aug.

6.

Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.

Chapel DB, Yamada SD, Cowan M, Lastra RR.

Gynecol Oncol. 2018 Jun;149(3):570-574. doi: 10.1016/j.ygyno.2018.04.005. Epub 2018 Apr 13.

PMID:
29656794
7.

Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.

Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, Yamada SD, Abumrad NA, Lengyel E.

Oncogene. 2018 Apr;37(17):2285-2301. doi: 10.1038/s41388-017-0093-z. Epub 2018 Feb 5.

8.

Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer.

Kim JS, Mills KA, Fehniger J, Liao C, Hurteau JA, Kirschner CV, Lee NK, Rodriguez GC, Yamada SD, Diaz Moore ES, Tenney ME.

Int J Gynecol Cancer. 2017 Oct;27(8):1774-1782. doi: 10.1097/IGC.0000000000001084.

PMID:
28708786
9.

Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.

Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL.

Cancer Prev Res (Phila). 2017 Apr;10(4):255-266. doi: 10.1158/1940-6207.CAPR-16-0281. Epub 2017 Mar 6.

10.

Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube.

Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E.

Cancer Discov. 2016 Dec;6(12):1342-1351. Epub 2016 Oct 7.

11.

Statin Use Significantly Improves Overall Survival in High-Grade Endometrial Cancer.

Feng CH, Miller CM, Tenney ME, Lee NK, Yamada SD, Hasan Y.

Int J Gynecol Cancer. 2016 Nov;26(9):1642-1649.

PMID:
27654261
12.

A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies.

Fehniger J, Thomas S, Lengyel E, Liao C, Tenney M, Oto A, Yamada SD.

Gynecol Oncol. 2016 Jul;142(1):169-175. doi: 10.1016/j.ygyno.2016.04.018. Epub 2016 Apr 28.

PMID:
27103176
13.

Nanoscale Coordination Polymers Codeliver Chemotherapeutics and siRNAs to Eradicate Tumors of Cisplatin-Resistant Ovarian Cancer.

He C, Poon C, Chan C, Yamada SD, Lin W.

J Am Chem Soc. 2016 May 11;138(18):6010-9. doi: 10.1021/jacs.6b02486. Epub 2016 May 2.

14.

Nanomedicine for Combination Therapy of Cancer.

He C, Chan C, Weichselbaum RR, Fleming GF, Yamada SD, Lin W.

EBioMedicine. 2015 May 13;2(5):366-7. doi: 10.1016/j.ebiom.2015.05.013. eCollection 2015 May. No abstract available.

15.

Patterns and utility of routine surveillance in high grade endometrial cancer.

Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD.

Gynecol Oncol. 2015 Jun;137(3):485-9. doi: 10.1016/j.ygyno.2015.03.047. Epub 2015 Mar 30.

16.

Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation.

Kennedy V, Abramsohn E, Makelarski J, Barber R, Wroblewski K, Tenney M, Lee NK, Yamada SD, Lindau ST.

Gynecol Oncol. 2015 Apr;137(1):119-24. doi: 10.1016/j.ygyno.2015.01.451. Epub 2015 Jan 9.

17.

Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus.

West AH, Yamada SD, MacMahon H, Acharya SS, Ali SM, He J, Lukas RV, Miller VA, Salgia R.

Case Rep Clin Pathol. 2014 Sep;1(2):151-154.

18.

Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.

Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, Wroblewski K, Yamada SD, Mazar AP, Bowtell D, Lengyel E.

J Clin Invest. 2014 Oct;124(10):4614-28. doi: 10.1172/JCI74778. Epub 2014 Sep 9.

19.

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH.

J Clin Oncol. 2014 Oct 10;32(29):3275-83. doi: 10.1200/JCO.2013.54.1987. Epub 2014 Sep 8.

20.

Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis.

Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L, Lengyel E, Romero IL.

PLoS One. 2014 Aug 13;9(8):e104521. doi: 10.1371/journal.pone.0104521. eCollection 2014.

21.

Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group.

Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, de Geest K, Gershenson DM.

Cancer. 2014 Feb 1;120(3):344-51. doi: 10.1002/cncr.28421. Epub 2013 Oct 24.

22.

A national network to advance the field of cancer and female sexuality.

Goldfarb SB, Abramsohn E, Andersen BL, Baron SR, Carter J, Dickler M, Florendo J, Freeman L, Githens K, Kushner D, Makelarski JA, Yamada SD, Lindau ST.

J Sex Med. 2013 Feb;10(2):319-25. doi: 10.1111/jsm.12061.

23.

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn DE, Harrison CR, Moore KN, Aghajanian C.

Gynecol Oncol. 2013 Apr;129(1):22-7. doi: 10.1016/j.ygyno.2012.12.022. Epub 2012 Dec 20.

PMID:
23262204
24.

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.

Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM.

Lancet Oncol. 2013 Feb;14(2):134-40. doi: 10.1016/S1470-2045(12)70572-7. Epub 2012 Dec 21.

25.

A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, Yamada SD, Armstrong DK, Fracasso PM, Walker JL.

Gynecol Oncol. 2012 Dec;127(3):506-10. doi: 10.1016/j.ygyno.2012.08.037. Epub 2012 Aug 31.

26.

Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure.

Tergas AI, Buell-Gutbrod R, Gwin K, Kocherginsky M, Temkin SM, Fefferman A, Lengyel E, Yamada SD.

Gynecol Oncol. 2012 Nov;127(2):316-20. doi: 10.1016/j.ygyno.2012.07.105. Epub 2012 Jul 24.

PMID:
22835717
27.

The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy.

Song S, Rudra S, Hasselle MD, Dorn PL, Mell LK, Mundt AJ, Yamada SD, Lee NK, Hasan Y.

Cancer. 2013 Jan 15;119(2):325-31. doi: 10.1002/cncr.27652. Epub 2012 Jul 17.

28.

Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization.

Bainer RO, Veneris JT, Yamada SD, Montag A, Lingen MW, Gilad Y, Rinker-Schaeffer CW.

Clin Exp Metastasis. 2012 Jun;29(5):397-408. doi: 10.1007/s10585-011-9448-y. Epub 2012 Feb 21.

29.

A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.

Rose PG, Sill MW, McMeekin DS, Ahmed A, Salani R, Yamada SD, Wolfson AH, Fusco N, Fracasso PM.

Gynecol Oncol. 2012 Apr;125(1):158-62. doi: 10.1016/j.ygyno.2011.12.431. Epub 2011 Dec 22.

30.

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, Somani N, Yamada SD, Tamby JF, Vergote I.

Lancet Oncol. 2012 Feb;13(2):154-62. doi: 10.1016/S1470-2045(11)70338-2. Epub 2011 Dec 20.

PMID:
22192729
31.

Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.

Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel E.

Obstet Gynecol. 2012 Jan;119(1):61-7. doi: 10.1097/AOG.0b013e3182393ab3.

32.

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL.

Gynecol Oncol. 2012 Apr;125(1):54-8. doi: 10.1016/j.ygyno.2011.12.417. Epub 2011 Dec 11.

33.

Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.

Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E.

Nat Med. 2011 Oct 30;17(11):1498-503. doi: 10.1038/nm.2492.

34.

Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.

Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM.

Gynecol Oncol. 2011 Nov;123(2):182-6. doi: 10.1016/j.ygyno.2011.07.016. Epub 2011 Aug 5.

35.

Assessing gynecologic and breast cancer survivors' sexual health care needs.

Hill EK, Sandbo S, Abramsohn E, Makelarski J, Wroblewski K, Wenrich ER, McCoy S, Temkin SM, Yamada SD, Lindau ST.

Cancer. 2011 Jun 15;117(12):2643-51. doi: 10.1002/cncr.25832. Epub 2010 Dec 23.

36.

Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.

Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T, Yamada SD, Peter ME, Lengyel E.

Clin Cancer Res. 2011 Jun 15;17(12):4042-51. doi: 10.1158/1078-0432.CCR-10-3387. Epub 2011 May 6.

37.

A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.

Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS.

Gynecol Oncol. 2011 May 1;121(2):264-8. doi: 10.1016/j.ygyno.2010.12.358. Epub 2011 Feb 1.

38.

The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma.

Bishop EA, Lengyel ER, Yamada SD, Montag A, Temkin SM.

Gynecol Oncol. 2011 Apr;121(1):218-23. doi: 10.1016/j.ygyno.2010.11.031. Epub 2010 Dec 17.

PMID:
21168200
39.

Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.

Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel E.

Clin Cancer Res. 2011 Feb 1;17(3):459-71. doi: 10.1158/1078-0432.CCR-10-2258. Epub 2010 Dec 13.

40.

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.

Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ.

J Clin Oncol. 2011 Jan 1;29(1):69-75. doi: 10.1200/JCO.2009.26.7856. Epub 2010 Nov 22.

41.

Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.

Kunos CA, Sill MW, Buekers TE, Walker JL, Schilder JM, Yamada SD, Waggoner SE, Mohiuddin M, Fracasso PM.

Gynecol Oncol. 2011 Feb;120(2):224-8. doi: 10.1016/j.ygyno.2010.10.018.

42.

A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.

Miller BE, Blessing JA, Stehman FB, Shahin MS, Yamada SD, Secord AA, Warshal DP, Abulafia O, Richards WE, Van Le L.

Gynecol Oncol. 2010 Aug 1;118(2):139-44. doi: 10.1016/j.ygyno.2010.03.024. Epub 2010 May 8.

PMID:
20452658
43.

A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.

Temkin SM, Yamada SD, Fleming GF.

Gynecol Oncol. 2010 Jun;117(3):473-6. doi: 10.1016/j.ygyno.2010.02.022. Epub 2010 Mar 28.

PMID:
20347480
44.

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.

De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE.

J Clin Oncol. 2010 Jan 1;28(1):149-53. doi: 10.1200/JCO.2009.24.1455. Epub 2009 Nov 16.

45.

{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer.

Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt MR, Montag AG, Kistner E, Yamada SD, Mitra AK, Lengyel E.

Am J Pathol. 2009 Nov;175(5):2184-96. doi: 10.2353/ajpath.2009.090028. Epub 2009 Oct 1.

46.

Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis.

Kenny HA, Dogan S, Zillhardt M, K Mitra A, Yamada SD, Krausz T, Lengyel E.

Cancer Treat Res. 2009;149:335-51. doi: 10.1007/978-0-387-98094-2_16. Review. No abstract available.

47.

A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.

Fiorica JV, Blessing JA, Puneky LV, Secord AA, Hoffman JS, Yamada SD, Buekers TE, Bell J, Schilder JM; Gynecologic Oncology Group.

Gynecol Oncol. 2009 Nov;115(2):285-9. doi: 10.1016/j.ygyno.2009.07.024. Epub 2009 Sep 2.

PMID:
19726073
48.

Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues.

Melhem A, Yamada SD, Fleming GF, Delgado B, Brickley DR, Wu W, Kocherginsky M, Conzen SD.

Clin Cancer Res. 2009 May 1;15(9):3196-204. doi: 10.1158/1078-0432.CCR-08-2131. Epub 2009 Apr 21.

49.

New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells.

Taylor JL, Szmulewitz RZ, Lotan T, Hickson J, Griend DV, Yamada SD, Macleod K, Rinker-Schaeffer CW.

Cancer Lett. 2008 Dec 8;272(1):12-22. doi: 10.1016/j.canlet.2008.05.012. Epub 2008 Jun 24. Review.

PMID:
18572308
50.

Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer.

Onujiogu N, Lengyel E, Yamada SD.

Gynecol Oncol. 2008 Dec;111(3):537-9. doi: 10.1016/j.ygyno.2008.04.032. Epub 2008 Jun 13.

PMID:
18554701

Supplemental Content

Loading ...
Support Center